Coltman Ca
About
In The Last Decade
Coltman Ca
25 papers receiving 803 citations
Peers
Comparison fields: 5 of 71
- Oncology 404
- Hematology 320
- Molecular Biology 274
- Pathology and Forensic Medicine 254
- Pulmonary and Respiratory Medicine 184
Countries citing papers authored by Coltman Ca
This map shows the geographic impact of Coltman Ca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coltman Ca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coltman Ca more than expected).
Fields of papers citing papers by Coltman Ca
This network shows the impact of papers produced by Coltman Ca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coltman Ca. The network helps show where Coltman Ca may publish in the future.
Co-authorship network of co-authors of Coltman Ca
This figure shows the co-authorship network connecting the top 25 collaborators of Coltman Ca. A scholar is included among the top collaborators of Coltman Ca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coltman Ca. Coltman Ca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. | 22 |
| 2 | Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. | 11 |
| 3 | Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study. | 3 |
| 4 | Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. | 52 |
| 5 | Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. | 31 |
| 6 | Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. | 8 |
| 7 | Evaluation of single-agent cisplatin in the management of non-small cell carcinoma of the lung: a Southwest Oncology Group Study. | 25 |
| 8 | Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. | 145 |
| 9 | Long-distance transportation of specimens for human tumor cloning. | 3 |
| 10 | Conclusions from clinical trials of the Southwest Oncology Group. | 22 |
| 11 | Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung. | 24 |
| 12 | Activity of mitoxantrone in a human tumor cloning system. | 79 |
| 13 | Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. | 19 |
| 14 | Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. | 37 |
| 15 | Evaluation of VP-16-213 in malignant lymphoma and melanoma. | 29 |
| 16 | Adriamycin and chlorambucil versus adriamycin and thiabendazole in the treatment of extensive, non-small cell carcinoma of the lung: a Southwest Oncology Group pilot study. | 2 |
| 17 | Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. | 48 |
| 18 | Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer. | 31 |
| 19 | Vinblastine (NSC-49842) and bleomycin (NSC-125066) therapy for disseminated testicular tumors. | 17 |
| 20 | Sweat collection in cystic fibrosis. Report of a simplified method employing pilocarpine iontophoresis and cellulose sponge. | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.